Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review

被引：26

作者：

Diedhiou, Demba ^{[1
,2
]}

Cuny, Thomas ^{[1
]}

Sarr, Anna ^{[2
]}

Diop, Said Norou ^{[2
]}

Klein, Marc ^{[1
]}

Weryha, Georges ^{[1
]}

机构：

[1] Lorraine Univ, Univ Hosp Ctr Nancy, Dept Endocrinol, Vandoeuvre Les Nancy, France

[2] Cheikh Anta Diop Univ, Univ Hosp Ctr Dakar, Dept Internal Med 2, Dakar, Senegal

来源：

ANNALES D ENDOCRINOLOGIE | 2015年 / 76卷 / 06期

关键词：

Osteoporosis; Denosumab; Fracture risk; Renal insufficiency; Safety; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; BIOCHEMICAL MARKERS; TURNOVER MARKERS; RISK REDUCTION; FRACTURE RISK; ALENDRONATE; THERAPY; MASS; PHASE-2;

D O I：

10.1016/j.ando.2015.10.009

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Denosumab is an anti-RANK ligand (RANKL) monoclonal antibody approved for the treatment of postmenopausal osteoporosis and prevention of skeletal metastasis complications. Administered subcutaneously every 6 months, it reduces the risk of vertebral fracture by 70% and of hip fracture by 40%. Its safety profile is acceptable. Denosumab may be used to treat patients with moderate to severe renal insufficiency. It has anti-fracture activity equivalent to that of zoledronic acid, but no residual effect, and no action at all beyond 6 months. In France, denosumab is reimbursed as a second-line treatment after a first attempt with bisphosphonate. (C) 2015 Elsevier Masson SAS. All rights reserved.

引用

页码：650 / 657

页数：8

共 50 条

[1] Efficacy and safety of denosumab and teriparatide treatment for osteoporosis: a systematic review and meta-analysis
Wang, Tao
Xuan, Zhaopeng
Li, Ruijun
Song, Liangsong
Dou, Yichen
Ren, Jingyan
Jia, Xueyuan
Lu, Laijin
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (04): : 5949 - 5956
[2] A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis
Miller, Paul D.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2011, 3 (06) : 271 - 282
[3] Denosumab for the treatment of osteoporosis: A systematic literature review
Silva-Fernandez, Lucia
Piedad Rosario, Maria
Antonio Martinez-Lopez, Juan
Carmona, Loreto
Loza, Estibaliz
REUMATOLOGIA CLINICA, 2013, 9 (01): : 42 - 52
[4] Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review
Chandran, Thulasi
Venkatachalam, Indumathi
SINGAPORE MEDICAL JOURNAL, 2019, 60 (07) : 364 - 378
[5] Efficacy and Safety of Denosumab in Postmenopausal Women with Osteopenia or Osteoporosis: A Systematic Review and a Meta-analysis
Anastasilakis, A. D.
Toulis, K. A.
Goulis, D. G.
Polyzos, S. A.
Delaroudis, S.
Giomisi, A.
Terpos, E.
HORMONE AND METABOLIC RESEARCH, 2009, 41 (10) : 721 - 729
[6] Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic Review
Nargesi, Shahin
Barghazan, Saeed Husseini
Sani'ee, Nadia
Kemmak, Asma Rashki
IRANIAN JOURNAL OF PUBLIC HEALTH, 2022, 51 (07) : 1502 - 1512
[7] Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
Anastasilakis, Athanasios D.
Toulis, Konstantinos A.
Polyzos, Stergios A.
Anastasilakis, Chrysostomos D.
Makras, Polyzois
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2012, 8 : 295 - 306
[8] A review of denosumab for the treatment of osteoporosis
Miyazaki, Tsuyoshi
Tokimura, Fumiaki
Tanaka, Sakae
PATIENT PREFERENCE AND ADHERENCE, 2014, 8 : 463 - 471
[9] Safety of Denosumab in Postmenopausal Osteoporosis and in Cancer and Bone Metastase Treatment: A Systematic Review and Meta-Analysis
Aubailly, Marlene
Combe, Bernard
Gaujoux-Viala, Cecile
Lukas, Cedric
Morel, Jacques
Che, Helene
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[10] The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review
Zhu, Yilin
Huang, Zhonglian
Wang, Yan
Xu, Weicai
Chen, Hongjiang
Xu, Jiankun
Luo, Shaowei
Zhang, Yuantao
Zhao, Di
Hu, Jun
JOURNAL OF ORTHOPAEDIC TRANSLATION, 2020, 22 : 7 - 13

← 1 2 3 4 5 →